Following on from the recent news of our entry into the Middle East, NGPOD is delighted to announce the agreement of a partnership with Nutritech to distribute the NGPOD nasogastric tube placement confirmation system in Singapore, Cambodia and Brunei.
Marcus Ineson, Chief Marketing Officer of NGPOD Global Ltd, said of the agreement, "This is a huge opportunity for NGPOD to enter a burgeoning healthcare market that is leading the way in the region; through investment in facilities and new technology."
Singapore's healthcare market is forecast to grow to $49.4 billion by 2029. This increase is driven by rising government spending on healthcare.
The quality of healthcare in Singapore is very high, with organisations like Singapore General Hospital, which was ranked as the third-best in the world in 2019 according to Newsweek Magazine.
NGPOD is a patented device that, in a UK-based clinical trial, has been shown to reduce the risks associated with established methods of nasogastric tube placement, which can lead to serious clinical incidents (Never Events) which cause injury and death to patients. NGPOD also reduces the need for time-consuming, costly x-rays and allows patients to receive nutrition, hydration and medicines without delay supporting their recovery.
NGPOD Ltd manufactures the NGPOD system in the UK and has so far, in 2022, created six new high-quality life science manufacturing jobs at their new facility in Runcorn. Further announcements of other international distribution partnerships are imminent.
For more information; Contact Us
WHAT IS NGPOD?